Business Context and Reporting Period
This Form 8-K Current Report was filed by Charles River Laboratories International, Inc. on September 12, 2025. The filing addresses a significant change in executive leadership within the finance department.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly an announcement of personnel changes.
Material Changes
- Resignation of CFO: Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer, has resigned effective September 29, 2025.
- Reason for Departure: The resignation is not the result of any disagreements with the Company regarding financial statements, internal controls, operations, policies, or practices.
- Interim Appointment: Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, has been appointed as Interim Chief Financial Officer effective upon Ms. Pease's departure.
Outlook, Risks, and Management Commentary
On September 16, 2025, the Company issued a press release (Exhibit 99.1) detailing the transition. The release includes "safe harbor" language regarding forward-looking statements. The filing notes that risks related to the Company are set forth in other documents filed with the SEC. No specific guidance or unusual financial items are disclosed in this report.
Investor Verification Checklist
- Verify the effective date of the CFO transition (September 29, 2025).
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Confirm that no disagreements regarding financial reporting exist, as explicitly stated in the filing.